Nobles Medical launches next-gen NobleStitch EL, touts 1,000th use
Nobles Medical Technologies this week announced the release of its next-generation NobleStitch EL patent foramen ovale/atrial septal defect closure device and said that its NobleStitch EL had been used in 1,000 patients.
The company said that data in a recently published article in EuroIntervention supported the use of the NobleStitch EL for closing the PFO and ASD without causing atrial fibrillation. Nobles added that in the more than 1,000 cases of PFO closure performed to date with the device, there have been no reports of device related complications and no atrial fibrillation.
“Our key opinion leaders have provided a great deal of feedback that we have integrated into this next generation design and they are extremely enthusiastic about the new NobleStitch EL2. With the recent publication of our data in EuroIntervention we have received tremendous interest to bring the NobleStitch EL2 to centers all over the world. Now we are rapidly training more proctors to meet tremendous demand we are experiencing and the NobleStitch EL2 will just make the process even easier!” CEO Anthony Nobles said in a prepared statement.
“The system was already very easy to introduce to our key opinion leaders and now with these new improvements it will make training easier and adoption even faster. We are very excited to see the rapid speed in which Nobles Medical reacts to customer feedback. This is one of the most revolutionary products we have ever sold and it is amazing that they could still improve on such a system,” Kardia, which distributes the NobleStitch EL2, sales director Roberto Riva said in a press release.
Nobles touted that the 1,000th person had been treated with the NobleStitch EL in a procedure that was part of a study performed by Dr. Jim Thompson of Virginia’s Inova Fairfax Hospital.
“I have not been this excited since medical school, the NobleStitch EL has changed how I approach cardio-vascular repair. I have never had a product where patients not only call me on a regular basis, but I have patients fly from all over the world requesting to have their procedures using the NobleStitch EL. This technology allows me to percutaneously suture the cardiac anatomy and I look forward to the expanded future applications in the heart,” Dr. Thompson said in a prepared release.
“This is a significant milestone for our company, reaching our 1,000th case without a single device related complication is a statement that we believe will have a game changing impact on the market. Additionally, as a manufacturer this demonstrates our ability to produce a quality product at a scale that allows us to compete with the larger companies. We continue to expand our indications and to offer new solutions for our physicians around the world,” CEO Nobles said in prepared remarks..